Search Results - "Laia Paré"

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma by Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia, Pardo, Nuria, Cedrés, Susana, Fan, Cheng, Parker, Joel S, Gaba, Lydia, Victoria, Iván, Viñolas, Nuria, Vivancos, Ana, Arance, Ana, Felip, Enriqueta

“…Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety of solid tumors, but most patients exhibit partial or…”
Get full text

Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer by Gendoo, Deena M A, Ratanasirigulchai, Natchar, Schröder, Markus S, Paré, Laia, Parker, Joel S, Prat, Aleix, Haibe-Kains, Benjamin

“…Breast cancer is one of the most frequent cancers among women. Extensive studies into the molecular heterogeneity of breast cancer have produced a plethora of…”
Get full text

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies by Prat, Aleix, Chaudhury, Anwesha, Solovieff, Nadia, Paré, Laia, Martinez, Débora, Chic, Nuria, Martínez-Sáez, Olga, Brasó-Maristany, Fara, Lteif, Agnes, Taran, Tetiana, Babbar, Naveen, Su, Fei

“…The prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast…”
Get full text

Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy by Prat, Aleix, Fan, Cheng, Fernández, Aranzazu, Hoadley, Katherine A, Martinello, Rossella, Vidal, Maria, Viladot, Margarita, Pineda, Estela, Arance, Ana, Muñoz, Montserrat, Paré, Laia, Cheang, Maggie C U, Adamo, Barbara, Perou, Charles M

“…Predicting treatment benefit and/or outcome before any therapeutic intervention has taken place would be clinically very useful. Herein, we evaluate the…”
Get full text

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial by Ciruelos, Eva, Villagrasa, Patricia, Pascual, Tomás, Oliveira, Mafalda, Pernas, Sonia, Paré, Laia, Escrivá-de-Romaní, Santiago, Manso, Luis, Adamo, Barbara, Martínez, Eduardo, Cortés, Javier, Vazquez, Silvia, Perelló, Antonia, Garau, Isabel, Melé, Mireia, Martínez, Noelia, Montaño, Alvaro, Bermejo, Begoña, Morales, Serafin, Echarri, María J, Vega, Estela, González-Farré, Blanca, Martínez, Débora, Galván, Patricia, Canes, Jordi, Nuciforo, Paolo, Gonzalez, Xavier, Prat, Aleix

“…To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer. PATRICIA is a…”
Get full text

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial by Adamo, Barbara, Bellet, Meritxell, Paré, Laia, Pascual, Tomás, Vidal, Maria, Pérez Fidalgo, José A, Blanch, Salvador, Martinez, Noelia, Murillo, Laura, Gómez-Pardo, Patricia, López-González, Ana, Amillano, Kepa, Canes, Jordi, Galván, Patricia, González-Farré, Blanca, González, Xavier, Villagrasa, Patricia, Ciruelos, Eva, Prat, Aleix

“…The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive…”
Get full text

De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial by Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Paré, Laia, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jóźwiak, Katarzyna, Zu Eulenburg, Christine, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemotherapy appears to be an option in selected…”
Get full text

Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes by HOSKINS, Janelle M, MARCUELLO, Eugenio, ALTES, Albert, MARSH, Sharon, MAXWELL, Taylor, VAN BOOVEN, Derek J, PARE, Laia, CULVERHOUSE, Robert, MCLEOD, Howard L, BAIGET, Montserrat

“…Purpose: Irinotecan is an important drug for the treatment of solid tumors. Although genes involved in irinotecan pharmacokinetics have been shown to influence…”
Get full text

Identification of ALK , ROS1 , and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients by Reguart, Noemí, Teixidó, Cristina, Giménez-Capitán, Ana, Paré, Laia, Galván, Patricia, Viteri, Santiago, Rodríguez, Sonia, Peg, Vicente, Aldeguer, Erika, Viñolas, Nuria, Remon, Jordi, Karachaliou, Niki, Conde, Esther, Lopez-Rios, Fernando, Nadal, Ernest, Merkelbach-Bruse, Sabine, Büttner, Reinhard, Rosell, Rafael, Molina-Vila, Miguel A, Prat, Aleix

“…Anaplastic lymphoma receptor tyrosine kinase ( ), ROS proto-oncogene 1, receptor tyrosine kinase ( ), and ret proto-oncogene ( ) fusions are present in 5%-7%…”
Get full text

Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial by Gluz, Oleg, Kolberg‐Liedtke, Cornelia, Prat, Aleix, Christgen, Matthias, Gebauer, Daniel, Kates, Ronald, Paré, Laia, Grischke, Eva‐Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Kuemmel, Sherko, Wuerstlein, Rachel, Pelz, Enrico, Nitz, Ulrike, Kreipe, Hans Heinrich, Harbeck, Nadia

“…In the neoadjuvant WSG‐ADAPT‐TN trial, 12‐week nab‐paclitaxel + carboplatin (nab‐pac/carbo) was highly effective and superior to nab‐paclitaxel + gemcitabine…”
Get full text

Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer by Dieci, Maria Vittoria, Conte, PierFranco, Bisagni, Giancarlo, Bartolini, Stefania, Frassoldati, Antonio, Generali, Daniele, Piacentini, Federico, Griguolo, Gaia, Tagliafico, Enrico, Brasó Maristany, Fara, Chic, Nuria, Paré, Laia, Miglietta, Federica, Vicini, Roberto, D’Amico, Roberto, Balduzzi, Sara, Prat, Aleix, Guarneri, Valentina

“…Abstract Background Even with contemporary treatment strategies, more than 10% of HER2-positive early stage breast cancer patients may experience distant…”
Get full text

PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2 + Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype by Guarneri, Valentina, Dieci, Maria Vittoria, Bisagni, Giancarlo, Brandes, Alba A, Frassoldati, Antonio, Cavanna, Luigi, Musolino, Antonino, Giotta, Francesco, Rimanti, Anita, Garrone, Ornella, Bertone, Elena, Cagossi, Katia, Nanni, Oriana, Piacentini, Federico, Orvieto, Enrico, Griguolo, Gaia, Curtarello, Matteo, Urso, Loredana, Paré, Laia, Chic, Nuria, D'Amico, Roberto, Prat, Aleix, Conte, Pierfranco

“…We explored the prognostic effect of mutation in HER2 patients enrolled in the ShortHER trial. The ShortHER trial randomized 1,253 patients with HER2 breast…”
Get full text

TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer by Reig, Òscar, Marín-Aguilera, Mercedes, Carrera, Gemma, Jiménez, Natalia, Paré, Laia, García-Recio, Susana, Gaba, Lydia, Pereira, Maria Verónica, Fernández, Pedro, Prat, Aleix, Mellado, Begoña

“…Abstract TMPRSS2-ERG rearrangement is a genetic alteration exclusive to prostate cancer, associated with taxane resistance in preclinical models. Its detection…”
Get full text

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver by Hruschka, Natascha, Kalisz, Mark, Subijana, Maria, Graña-Castro, Osvaldo, Del Cano-Ochoa, Francisco, Brunet, Laia Paré, Chernukhin, Igor, Sagrera, Ana, De Reynies, Aurelien, Kloesch, Bernhard, Chin, Suet-Feung, Burgués, Octavio, Andreu, David, Bermejo, Begoña, Cejalvo, Juan Miguel, Sutton, Joe, Caldas, Carlos, Ramón-Maiques, Santiago, Carroll, Jason S., Prat, Aleix, Real, Francisco X., Martinelli, Paola

“…As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be…”
Get full text

HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 by Brasó-Maristany, Fara, Griguolo, Gaia, Chic, Nuria, Pascual, Tomás, Paré, Laia, Maues, Julia, Galván, Patricia, Dieci, Maria Vittoria, Miglietta, Federica, Giarratano, Tommaso, Martínez-Sáez, Olga, Marín-Aguilera, Mercedes, Schettini, Francesco, Conte, Benedetta, Angelats, Laura, Vidal, Maria, Adamo, Barbara, Muñoz, Montserrat, Sanfeliu, Esther, González, Blanca, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S, Perou, Charles M, Conte, PierFranco, Prat, Aleix, Guarneri, Valentina

“…Abstract In advanced HER2-positive (HER2+) breast cancer, the new antibody-drug conjugate trastuzumab deruxtecan is more effective compared with trastuzumab…”
Get full text

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer by Quintana, Ángela, Peg, Vicente, Prat, Aleix, Moliné, Teresa, Villacampa, Guillermo, Paré, Laia, Galván, Patricia, Dientsmann, Rodrigo, Schmid, Peter, Curigliano, Giuseppe, Muñoz-Couselo, Eva, Perez-García, José, Marti, Merce, Blanco-Heredia, Juan, Anjos, Carla dos, Vazquez, Miguel, De Mattos-Arruda, Leticia, Cortés, Javier

“…Triple-negative breast cancer (TNBC) is a subtype of breast cancer with unmet medical needs. Several studies have proved that high levels of tumor infiltrating…”
Get full text

Identification of candidate susceptibility genes for colorectal cancer through eQTL analysis by Closa, Adria, Cordero, David, Sanz-Pamplona, Rebeca, Solé, Xavier, Crous-Bou, Marta, Paré-Brunet, Laia, Berenguer, Antoni, Guino, Elisabet, Lopez-Doriga, Adriana, Guardiola, Jordi, Biondo, Sebastiano, Salazar, Ramon, Moreno, Victor

“…In this study, we aim to identify the genes responsible for colorectal cancer risk behind the loci identified in genome-wide association studies (GWAS). These…”
Get full text

Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2 by Prat, Aleix, Brase, Jan Christoph, Cheng, Yuan, Nuciforo, Paolo, Paré, Laia, Pascual, Tomás, Martínez, Débora, Galván, Patricia, Vidal, Maria, Adamo, Barbara, Hortobagyi, Gabriel N., Baselga, José, Ciruelos, Eva

“…Background The prognostic and predictive value of the two nonluminal (human epidermal growth factor receptor 2 [HER2]‐enriched and basal‐like) subtypes within…”
Get full text

Management of early-stage HER2-positive breast cancer and attitudes towards HER2DX test in Spain: insights from a nationwide survey by Martínez-Sáez, Olga, Cortés, Javier, Ciruelos, Eva, Marín-Aguilera, Mercedes, González, Gloria, Paré, Laia, Herrera, Adriana, Villagrasa-González, Patricia, Prat, Aleix, Martín, Miguel

“…Purpose This study aimed to investigate the current therapeutic management of patients with early-stage HER2-positive (HER2+) breast cancer in Spain, while…”
Get full text

Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease by Isola, Ignacio, Brasó-Maristany, Fara, Moreno, David F, Mena, Mari-Pau, Oliver-Calders, Aina, Paré, Laia, Rodríguez-Lobato, Luis Gerardo, Martin-Antonio, Beatriz, Cibeira, María Teresa, Bladé, Joan, Rosiñol, Laura, Prat, Aleix, Lozano, Ester, Fernández de Larrea, Carlos

“…We previously reported algorithms based on clinical parameters and plasma cell characteristics to identify patients with smoldering multiple myeloma (SMM) with…”
Get full text